메뉴 건너뛰기




Volumn 15, Issue 6, 2014, Pages 719-722

Warfarin pharmacogenetic trials: Is there a future for pharmacogenetic- guided dosing?

Author keywords

clinical utility; CYP2C9; pharmacogenetics; pharmacogenomics; randomized controlled clinical trial; VKORC1; warfarin

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

EID: 84901990017     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.18     Document Type: Review
Times cited : (22)

References (19)
  • 1
    • 84889873119 scopus 로고    scopus 로고
    • A randomized trial of genotype-guided dosing of warfarin
    • Pirmohamed M, Burnside G, Eriksson N et al. A randomized trial of genotype-guided dosing of warfarin. N. Engl. J. Med. 369(24), 2294-2303 (2013).
    • (2013) N. Engl. J. Med. , vol.369 , Issue.24 , pp. 2294-2303
    • Pirmohamed, M.1    Burnside, G.2    Eriksson, N.3
  • 2
    • 84889824971 scopus 로고    scopus 로고
    • A pharmacogenetic versus a clinical algorithm for warfarin dosing
    • Kimmel SE, French B, Kasner SE et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N. Engl. J. Med. 369(24), 2283-2293 (2013).
    • (2013) N. Engl. J. Med. , vol.369 , Issue.24 , pp. 2283-2293
    • Kimmel, S.E.1    French, B.2    Kasner, S.E.3
  • 3
    • 84856699090 scopus 로고    scopus 로고
    • Executive summary: Antithrombotic Therapy and Prevention of Thrombosis (9th Edition): American college of chest physicians evidence-based clinical practice guidelines
    • Guyatt GH, Akl EA, Crowther M et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis (9th Edition): American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(Suppl. 2), S7-S47 (2012).
    • (2012) Chest , vol.141 , Issue.SUPPL. 2
    • Guyatt, G.H.1    Akl, E.A.2    Crowther, M.3
  • 4
    • 0037732826 scopus 로고    scopus 로고
    • American Heart Association/American College of Cardiology Foundation guide to warfarin therapy
    • Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J. Am. Coll. Cardiol. 41(9), 1633-1652 (2003).
    • (2003) J. Am. Coll. Cardiol. , vol.41 , Issue.9 , pp. 1633-1652
    • Hirsh, J.1    Fuster, V.2    Ansell, J.3    Halperin, J.L.4
  • 6
    • 0033608466 scopus 로고    scopus 로고
    • Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    • Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353(9154), 717-719 (1999).
    • (1999) Lancet , vol.353 , Issue.9154 , pp. 717-719
    • Aithal, G.P.1    Day, C.P.2    Kesteven, P.J.3    Daly, A.K.4
  • 7
    • 21144448879 scopus 로고    scopus 로고
    • Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
    • Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285-2293 (2005).
    • (2005) N. Engl. J. Med. , vol.352 , Issue.22 , pp. 2285-2293
    • Rieder, M.J.1    Reiner, A.P.2    Gage, B.F.3
  • 8
    • 47949086046 scopus 로고    scopus 로고
    • Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
    • Gage BF, Eby C, Johnson JA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008).
    • (2008) Clin. Pharmacol. Ther. , vol.84 , Issue.3 , pp. 326-331
    • Gage, B.F.1    Eby, C.2    Johnson, J.A.3
  • 9
    • 60849097257 scopus 로고    scopus 로고
    • Estimation of the warfarin dose with clinical and pharmacogenetic data
    • International Warfarin Pharmacogenetics Consortium
    • International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
    • (2009) N. Engl. J. Med. , vol.360 , Issue.8 , pp. 753-764
    • Klein, T.E.1    Altman, R.B.2
  • 10
    • 63449117825 scopus 로고    scopus 로고
    • A genome-wide association study confirms VKORC1 CYP2C9 and CYP4F2 as principal genetic determinants of warfarin dose
    • Takeuchi F, Mcginnis R, Bourgeois S et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5(3), e1000433 (2009).
    • (2009) PLoS Genet. , vol.5 , Issue.3
    • Takeuchi, F.1    McGinnis, R.2    Bourgeois, S.3
  • 11
    • 59649117935 scopus 로고    scopus 로고
    • The largest prospective warfarin-treated cohort supports genetic forecasting
    • Wadelius M, Chen LY, Lindh JD et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4), 784-792 (2009).
    • (2009) Blood , vol.113 , Issue.4 , pp. 784-792
    • Wadelius, M.1    Chen, L.Y.2    Lindh, J.D.3
  • 12
    • 77953304931 scopus 로고    scopus 로고
    • Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study)
    • Epstein RS, Moyer TP, Aubert RE et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 55(25), 2804-2812 (2010).
    • (2010) J. Am. Coll. Cardiol. , vol.55 , Issue.25 , pp. 2804-2812
    • Epstein, R.S.1    Moyer, T.P.2    Aubert, R.E.3
  • 13
    • 80052930568 scopus 로고    scopus 로고
    • Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy
    • Gong IY, Tirona RG, Schwarz UI et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 118(11), 3163-3171 (2011).
    • (2011) Blood , vol.118 , Issue.11 , pp. 3163-3171
    • Gong, I.Y.1    Tirona, R.G.2    Schwarz, U.I.3
  • 14
    • 36549030324 scopus 로고    scopus 로고
    • Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation
    • Anderson JL, Horne BD, Stevens SM et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22), 2563-2570 (2007).
    • (2007) Circulation , vol.116 , Issue.22 , pp. 2563-2570
    • Anderson, J.L.1    Horne, B.D.2    Stevens, S.M.3
  • 15
    • 79959189730 scopus 로고    scopus 로고
    • A randomized controlled trial of genotype-based Coumadin initiation
    • Burmester JK, Berg RL, Yale SH et al. A randomized controlled trial of genotype-based Coumadin initiation. Genet. Med. 13(6), 509-518 (2011).
    • (2011) Genet. Med. , vol.13 , Issue.6 , pp. 509-518
    • Burmester, J.K.1    Berg, R.L.2    Yale, S.H.3
  • 16
    • 84862777241 scopus 로고    scopus 로고
    • A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II)
    • Anderson JL, Horne BD, Stevens SM et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 125(16), 1997-2005 (2012).
    • (2012) Circulation , vol.125 , Issue.16 , pp. 1997-2005
    • Anderson, J.L.1    Horne, B.D.2    Stevens, S.M.3
  • 17
    • 84901250896 scopus 로고    scopus 로고
    • Ethnicity-specific pharmacogenetics: The case of warfarin in African Americans
    • doi:10.1038/tpj.2013.34 Epub ahead of print
    • Hernandez W, Gamazon ER, Aquino-Michaels K et al. Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. Pharmacogenom. J. doi:10.1038/tpj.2013.34 (2013) (Epub ahead of print).
    • (2013) Pharmacogenom. J.
    • Hernandez, W.1    Gamazon, E.R.2    Aquino-Michaels, K.3
  • 18
    • 84866738499 scopus 로고    scopus 로고
    • Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): Rationale and study design
    • Do EJ, Lenzini P, Eby CS et al. Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J. 12(5), 417-424 (2012).
    • (2012) Pharmacogenomics J. , vol.12 , Issue.5 , pp. 417-424
    • Do, E.J.1    Lenzini, P.2    Eby, C.S.3
  • 19
    • 79959260078 scopus 로고    scopus 로고
    • Clinical trials for pharmacogenomics testing for warfarin dosing: Relevance to general community practices
    • Sidiropoulos N, Wu AH. Clinical trials for pharmacogenomics testing for warfarin dosing: relevance to general community practices. Genet. Med. 13(6), 505-508 (2011).
    • (2011) Genet. Med. , vol.13 , Issue.6 , pp. 505-508
    • Sidiropoulos, N.1    Wu, A.H.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.